China Pharma Holdings $CPHI Read from its own SEC filings · nothing written, nothing inferred
🫧 Edgar looked up CHINA PHARMA HOLDINGS, INC. ($CPHI). Last filing: 10-Q, 2026-08-14. 6 event filings (8-K) in the past twelve months.
🔖 Exposure: revenue $4.1M (FY2025). Experience: revenue down 8.5% on the year, down 19.0% a year over 4 years; operating margin -78.2%, up from -101.3%. Soundness: equity 73.4% of assets, return on equity -14.0%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $2.3M and $5.3M next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; on a year the method never saw, 83.4% landed inside). In a shock year the stress range is $2.1M to $5.6M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -78.2% against a -3.8% median; growth -8.5% against 13.7%.
Speed and cash · fiscal 2025
Both views must agree for a label · a description, not advice.
| Cash flow (op · inv · fin · free) | $0M · −$0M · −$0M · $0M |
| Investment book (cash · short · long) | $0M · — · — · current ratio 0.32 |
| Revenue swing · equity of assets | 14.7% · 73.4% |
China Pharma Holdings is growing slower than its size class, with steadier revenue. Its own audited SEC figures.
The figures, as filed
| Fiscal year end | 2025-12-31 |
| Revenue | $4M |
| Revenue, on the year | −8.5% |
| Revenue, a year over the record | −19.0% |
| Operating margin | −78.2% |
| Operating margin, prior year | −101.3% |
| Net margin | −76.9% |
| Research and development | $0M · 6.8% of revenue |
| Total debt | — |
| Equity of assets | 73.4% |
| Return on equity | −14.0% |
| Payout of profit | — |
| Dividend per share | — |
| Earnings per share | $-0.74 |
| Book value per share | $5.30 |
| Revenue per share | $0.97 |
| Shares outstanding | 4,291,427 |
| Audited years read | 5 |
Peers: the median of 114 filers with $50M+ revenue in pharmaceutical preparations.
Health HarborChina Pharma Holdings sails as: Weathered boat
Health watch · 12 monthsLate annual report notice
Sailing speed follows growth: -20.0% a year crosses the harbor in 120 seconds.
🌊 Visit the Bay →- filed late annual report notice in the last 12 months
- revenue is hard to predict: its 80% range is ±40%
Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.
- 10-Q · 2026-08-14
- 8-K · 2026-07-22 · 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; 9.01 Financial Statements and Exhibits
- 10-Q · 2026-05-15
- 10-K · 2026-04-01
- 8-K · 2026-03-03 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits
- 8-K · 2026-02-10 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits
Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · ask about another company